1 / 21

Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without cetuximab. Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting.

chas
Télécharger la présentation

Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without cetuximab Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

  2. Disclosure Information<br />Relationships Relevant to this Session Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

  3. CRYSTAL study design Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

  4. Background Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

  5. RAS mutation analysis: BEAMing Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

  6. RAS mutation analysis: BEAMing Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

  7. Study profile Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

  8. Other RAS mutations: CRYSTAL Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

  9. Other RAS mutations: first-line studies Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

  10. Comparison of RAS subgroups: <br />efficacy Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

  11. Baseline characteristics Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

  12. Efficacy: RAS subgroups Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

  13. Efficacy: RAS subgroups Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

  14. Progression-free survival Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

  15. Progression-free survival Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

  16. Overall survival Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

  17. Overall survival Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

  18. Efficacy: RAS subgroups Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

  19. Safety: grade 3/4 adverse events Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

  20. Conclusions Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

  21. Acknowledgments Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

More Related